Drugs & Targets Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics October 11, 2024Vol.50 No.38
Drugs & Targets FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Retevmo for medullary thyroid cancer with RET mutation October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Cologuard Plus Test for non-invasive CRC screening October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Sarclisa + VRd for MM not eligible for transplant September 27, 2024Vol.50 No.36
Drugs & Targets EC approves Vyloy + chemo for advanced gastric and GEJ cancers September 27, 2024Vol.50 No.36
Drugs & Targets EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers September 27, 2024Vol.50 No.36
Drugs & Targets Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC September 27, 2024Vol.50 No.36
Drugs & Targets FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication September 20, 2024Vol.50 No.35
